Dr. Lynn Puana advances psilocybin research and physician-led mental health care

Colorado physician Dr. Lynn Puana is linking psilocybin research with supervised clinical care through PICMI and S&G Labs in Denver. The work combines lab testing, cognitive assessment, and patient care as interest grows in psychedelic medicine for brain health, mental wellness, and chronic pain.

Why it matters: - Dr. Lynn Puana is trying to narrow the gap between early psilocybin research and physician-led care. - The work could help define where psychedelic medicine may fit in brain health, mental health, and chronic pain management. - The research also underscores the difference between promising signals and established clinical evidence.

What happened: - Dr. Lynn Puana, MD, founder of Premier Integrative & Cognitive Medical Institute (PICMI) and S&G Labs, is advancing psilocybin-related research and supervised treatment programs in Colorado. - On October 2, 2026, Dr. Lynn Puana presented at the Texas Pain Society meeting in Dallas on psilocybin research and its possible relevance to chronic pain, neuroplasticity, central sensitization, and the psychological side of persistent pain. - PICMI in Denver offers physician-led brain health and mental wellness services that include screening, care planning, preparation, integration, and licensed psilocybin facilitation within Colorado's regulated natural medicine framework.

The details: - A research collaboration involving PICMI, S&G Labs, and Alan Wu, PhD, at the University of California, San Francisco is examining biological and cognitive responses linked to psilocybin. - The study is measuring brain-derived neurotrophic factor (BDNF), pro-BDNF, psilocin pharmacokinetics, and standardized cognitive assessments. - S&G Labs is providing laboratory and analytical support under the research protocol. - The collaboration is looking for links between biological markers and cognitive performance. - Dr. Lynn Puana said the work is meant to strengthen the scientific foundation of psychedelic medicine and identify questions that need further study. - Additional controlled research is still needed to establish clinical effectiveness, safety, and appropriate uses. - At PICMI, patient assessments may include cognitive testing, quantitative electroencephalography (qEEG) brain mapping, neurofeedback, genomic testing, and other evaluations when clinically appropriate. - Dr. Lynn Puana has more than two decades of experience in internal medicine, interventional pain management, and addiction medicine. - PICMI also documents patient perspectives through testimonial videos and podcast discussions featuring people describing depression, chronic pain, trauma, and neurological illness. - Those accounts are intended to complement, not replace, objective outcome measures and controlled clinical research. - PICMI and S&G Labs describe their shared goal as advancing understanding of complex health conditions through evidence-informed evaluation and continued research. - More information is available on the institute's website and PICMI's Facebook page.

Between the lines: - The approach blends research, clinic care, and patient storytelling, which could help build a broader case for or against psilocybin's medical use. - The emphasis on screening, follow-up, and integration suggests the clinic is positioning psilocybin as one part of a larger care model rather than a stand-alone fix. - By pairing lab markers with patient experience, PICMI is aiming to generate data that may be useful to future studies even if current evidence remains incomplete.

What's next: - The research collaboration is expected to continue analyzing whether biological changes track with cognitive shifts. - Future findings may help shape later studies on psilocybin in chronic pain and mental health. - PICMI is likely to keep combining physician oversight, diagnostic testing, and patient education as the field develops. - Dr. Lynn Puana indicated that more research will be needed before clinical decisions can rest on a stronger evidence base.

The bottom line: - PICMI and S&G Labs are pushing psilocybin research toward a more clinical, physician-led model, but the science is still early.